---
schema_version: "secwatch.filing_event.v1"
accession: "0001055726-26-000009"
form_type: "8-K"
ticker: "INO"
cik: "0001055726"
company_name: "INOVIO PHARMACEUTICALS, INC."
filed_at: "2026-03-12T23:59:59+00:00"
generated_at: "2026-05-15T12:52:41.043650+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Inovio reports FY 2025 net loss $84.9M; INO-3107 BLA accepted with PDUFA Oct 30, 2026

## Summary
- Q4 2025 net income $3.8M ($0.06 basic EPS) mainly from $21.2M non-cash warrant gain; FY net loss $84.9M ($1.81/share).
- Cash, equivalents & short-term investments $58.5M as of Dec 31, 2025; estimated runway into Q4 2026 with Q1 2026 burn ~$22M.
- FDA accepted BLA for INO-3107 under accelerated approval program; PDUFA date Oct 30, 2026; FDA questioned accelerated eligibility.
- Published INO-3107 Phase 1/2 and long-term data in Nature Communications and The Laryngoscope showing reduced surgeries.
- Entered clinical trial collaboration with Akeso to evaluate INO-5412 + cadonilimab for glioblastoma in Dana-Farber INSIGhT trial.

## SEC filing metadata
- accession: 0001055726-26-000009
- form_type: 8-K
- ticker: INO
- cik: 0001055726
- company_name: INOVIO PHARMACEUTICALS, INC.
- filed_at: 2026-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1055726/000105572626000009/0001055726-26-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1055726/000105572626000009/ino-20260312.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001055726-26-000009
- JSON: https://secwatch.observer/filing/0001055726-26-000009.json
- Plain text: https://secwatch.observer/filing/0001055726-26-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.